Rather than start with a novel biological target with minimal validation, New Path starts with well validated targets where chemistry to access molecules is preventing translation to medicine. We then use our technology platform of machine assisted chemistry to break the area open. Many of the molecules we work on are complex natural products and have previously only been produced biologically.